NeuroVive slides after dropping CicloMulsion for AKI

NeuroVive Pharmaceutical AB (SSE:NVP; Pink:NEVPF) fell SEK2.68 (44%) to SEK3.42 on Thursday after the company said it will discontinue development of CicloMulsion for acute kidney injury. The therapy missed the primary endpoint and had "no benefit" vs. placebo in the Phase II CiPRICS study to prevent AKI in patients undergoing open heart surgery, Neurovive said.

CicloMulsion is a Cremophor-free IV cyclosporine formulation. It previously missed the primary composite endpoint of improving clinical outcomes in a Phase III study in acute myocardial infarction (MI) patients undergoing percutaneous coronary intervention (PCI). ...